Defining the transcriptome of PIK3CA-altered cells in a human capillary malformation using single cell long-read sequencing.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 Oct 2024
Historique:
received: 07 03 2024
accepted: 04 09 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

PIK3CA-related overgrowth spectrum (PROS) disorders are caused by somatic mosaic variants that result in constitutive activation of the phosphatidylinositol-3-kinase/AKT/mTOR pathway. Promising responses to molecularly targeted therapy have been reported, although identification of an appropriate agent can be hampered by the mosaic nature and corresponding low variant allele frequency of the causal variant. Moreover, our understanding of the molecular consequences of these variants-for example how they affect gene expression profiles-remains limited. Here we describe in vitro expansion of a human capillary malformation followed by molecular characterization using exome sequencing, single cell gene expression, and targeted long-read single cell RNA-sequencing in a patient with clinical features consistent with Megalencephaly-Capillary Malformation Syndrome (MCAP, a PROS condition). These approaches identified a targetable PIK3CA variant with expression restricted to PAX3+ fibroblast and undifferentiated keratinocyte populations. This study highlights the innovative combination of next-generation single cell sequencing methods to better understand unique transcriptomic profiles and cell types associated with MCAP, revealing molecular intricacies of this genetic syndrome.

Identifiants

pubmed: 39455600
doi: 10.1038/s41598-024-72167-8
pii: 10.1038/s41598-024-72167-8
doi:

Substances chimiques

Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137
PAX3 Transcription Factor 0
PAX3 protein, human 0

Types de publication

Journal Article Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

25440

Informations de copyright

© 2024. The Author(s).

Références

Cottrell, C. E. et al. Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth. Genet. Med. 23(10), 1882–1888 (2021).
pubmed: 34040190 pmcid: 8486672 doi: 10.1038/s41436-021-01211-z
Davis, S. et al. Growth hormone deficiency in megalencephaly-capillary malformation syndrome: An association with activating mutations in PIK3CA. Am. J. Med. Genet. A 182(1), 162–168 (2020).
pubmed: 31729162 doi: 10.1002/ajmg.a.61403
McNulty, S. N. et al. Diagnostic utility of next-generation sequencing for disorders of somatic mosaicism: A five-year cumulative cohort. Am. J. Hum. Genet. 105(4), 734–746 (2019).
pubmed: 31585106 pmcid: 6817554 doi: 10.1016/j.ajhg.2019.09.002
Park, H. J. et al. Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations. Orphanet. J. Rare Dis. 15(1), 205 (2020).
pubmed: 32778138 pmcid: 7418424 doi: 10.1186/s13023-020-01480-y
Riviere, J. B. et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 44(8), 934–940 (2012).
pubmed: 22729224 pmcid: 3408813 doi: 10.1038/ng.2331
Zenner, K. et al. Somatic activating BRAF variants cause isolated lymphatic malformations. HGG Adv. 3(2), 100101 (2022).
pubmed: 35373151 pmcid: 8972000
Peyre, M. et al. Somatic PIK3CA mutations in sporadic cerebral cavernous malformations. N. Engl. J. Med. 385(11), 996–1004 (2021).
pubmed: 34496175 pmcid: 8606022 doi: 10.1056/NEJMoa2100440
Weng, J. et al. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation. Am. J. Hum. Genet. 108(5), 942–950 (2021).
pubmed: 33891857 pmcid: 8206158 doi: 10.1016/j.ajhg.2021.04.005
Nikolaev, S. I., Fish, J. E. & Radovanovic, I. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N. Engl. J. Med. 378(16), 1561–1562 (2018).
pubmed: 29669234 doi: 10.1056/NEJMc1802190
Priemer, D. S. et al. Activating KRAS mutations in arteriovenous malformations of the brain: Frequency and clinicopathologic correlation. Hum. Pathol. 89, 33–39 (2019).
pubmed: 31026472 doi: 10.1016/j.humpath.2019.04.004
Deleu, T., Jansen, K. & Calenbergh, F. V. Brain overgrowth associated with megalencephaly-capillary malformation syndrome causing progressive Chiari and syringomyelia. Surg. Neurol. Int. 13, 211 (2022).
pubmed: 35673641 pmcid: 9168292 doi: 10.25259/SNI_1016_2021
Loughan, A. R., Harrell, M., Perna, R., Allen, A. & Suddarth, B. Megalencephaly-capillary malformation polymicrogyria: A review and complex pediatric case report. Appl. Neuropsychol. Child. 6(4), 369–377 (2017).
pubmed: 27216985 doi: 10.1080/21622965.2016.1182432
Mirzaa, G. M. et al. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: Two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am. J. Med. Genet. A 158A(2), 269–291 (2012).
pubmed: 22228622 doi: 10.1002/ajmg.a.34402
Mirzaa, G. M. & Dobyns, W. B. The “megalencephaly-capillary malformation” (MCAP) syndrome: The nomenclature of a highly recognizable multiple congenital anomaly syndrome. Am. J. Med. Genet. A 161A(8), 2115–2116 (2013).
pubmed: 23798482 doi: 10.1002/ajmg.a.35940
Sarma, K., Nayak, M. K., Mishra, B. & Gaikwad, S. B. Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP): A rare dynamic genetic disorder. Cureus 14(5), e25123 (2022).
pubmed: 35733479 pmcid: 9205759
St John, L. J. & Rao, N. Autism spectrum disorder in a child with megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP). BMJ Case Rep. 14(12), e247034 (2021).
pubmed: 34969807 pmcid: 8719146 doi: 10.1136/bcr-2021-247034
Edwards, E. A. et al. Monitoring arteriovenous malformation response to genotype-targeted therapy. Pediatrics 146, 3 (2020).
doi: 10.1542/peds.2019-3206
Lekwuttikarn, R., Lim, Y. H., Admani, S., Choate, K. A. & Teng, J. M. C. Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol. 155(2), 256–257 (2019).
pubmed: 30566190 pmcid: 7186908 doi: 10.1001/jamadermatol.2018.4653
Li, D. et al. Genomic profiling informs diagnoses and treatment in vascular anomalies. Nat. Med. 29(6), 1530–1539 (2023).
pubmed: 37264205 pmcid: 11184491 doi: 10.1038/s41591-023-02364-x
Venot, Q. et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 558(7711), 540–546 (2018).
pubmed: 29899452 pmcid: 7610773 doi: 10.1038/s41586-018-0217-9
Venot, Q. et al. Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 568(7752), E6 (2019).
pubmed: 30944482 doi: 10.1038/s41586-019-1109-3
Chen, W. L. et al. The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: A case report. Cold Spring Harb. Mol. Case Stud. 8, 3 (2022).
Zenner, K. et al. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations. Genet. Med. 23(1), 123–130 (2021).
pubmed: 32884133 doi: 10.1038/s41436-020-00943-8
Palmieri, M. et al. Cell-free DNA next-generation sequencing liquid biopsy as a new revolutionary approach for arteriovenous malformation. JVS Vasc. Sci. 1, 176–180 (2020).
pubmed: 34617046 pmcid: 8489236 doi: 10.1016/j.jvssci.2020.08.002
Chang, F. et al. Molecular diagnosis of mosaic overgrowth syndromes using a custom-designed next-generation sequencing panel. J. Mol. Diagn. 19(4), 613–624 (2017).
pubmed: 28502725 doi: 10.1016/j.jmoldx.2017.04.006
Kuentz, P. et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet. Med. 19(9), 989–997 (2017).
pubmed: 28151489 doi: 10.1038/gim.2016.220
Morita, H. & Komuro, I. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N. Engl. J. Med. 378(16), 1561 (2018).
pubmed: 29671469 doi: 10.1056/NEJMc1802190
Nam, A. S. et al. Somatic mutations and cell identity linked by genotyping of transcriptomes. Nature 571(7765), 355–360 (2019).
pubmed: 31270458 pmcid: 6782071 doi: 10.1038/s41586-019-1367-0
Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23(6), 692–702 (2017).
pubmed: 28504724 doi: 10.1038/nm.4336
Cheow, L. F. et al. Single-cell multimodal profiling reveals cellular epigenetic heterogeneity. Nat. Methods 13(10), 833–836 (2016).
pubmed: 27525975 doi: 10.1038/nmeth.3961
Al’Khafaji, A. M. et al. High-throughput RNA isoform sequencing using programmed cDNA concatenation. Nat. Biotechnol. 42, 582 (2023).
pubmed: 37291427 doi: 10.1038/s41587-023-01815-7
Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19(1), 4–23 (2017).
pubmed: 27993330 pmcid: 5707196 doi: 10.1016/j.jmoldx.2016.10.002
Wang, S. et al. Single cell transcriptomics of human epidermis identifies basal stem cell transition states. Nat. Commun. 11(1), 4239 (2020).
pubmed: 32843640 pmcid: 7447770 doi: 10.1038/s41467-020-18075-7
Nguyen, B. C. et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20(8), 1028–1042 (2006).
pubmed: 16618808 pmcid: 1472299 doi: 10.1101/gad.1406006
Zhou, B. et al. Notch signaling pathway: Architecture, disease, and therapeutics. Signal Transduct. Target Ther. 7(1), 95 (2022).
pubmed: 35332121 pmcid: 8948217 doi: 10.1038/s41392-022-00934-y
Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).
pubmed: 15016963 doi: 10.1126/science.1096502
Janku, F. et al. PIK3CA mutations in advanced cancers: Characteristics and outcomes. Oncotarget 3(12), 1566–1575 (2012).
pubmed: 23248156 pmcid: 3681495 doi: 10.18632/oncotarget.716
Garcia, Z., Kumar, A., Marques, M., Cortes, I. & Carrera, A. C. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J. 25(4), 655–661 (2006).
pubmed: 16437156 pmcid: 1383550 doi: 10.1038/sj.emboj.7600967
Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105(7), 2652–2657 (2008).
pubmed: 18268322 pmcid: 2268191 doi: 10.1073/pnas.0712169105
Zhao, L. & Vogt, P. K. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): Differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9(3), 596–600 (2010).
pubmed: 20009532 doi: 10.4161/cc.9.3.10599
Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19(11), 2537–2548 (2000).
pubmed: 10835352 pmcid: 212739 doi: 10.1093/emboj/19.11.2537
Fingar, D. C., Salama, S., Tsou, C., Harlow, E. & Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16(12), 1472–1487 (2002).
pubmed: 12080086 pmcid: 186342 doi: 10.1101/gad.995802
Saucedo, L. J. & Edgar, B. A. Why size matters: Altering cell size. Curr. Opin. Genet. Dev. 12(5), 565–571 (2002).
pubmed: 12200162 doi: 10.1016/S0959-437X(02)00341-6
Wiedemann, J. et al. Differential cell composition and split epidermal differentiation in human palm, sole, and hip skin. Cell Rep. 42(1), 111994 (2023).
pubmed: 36732947 pmcid: 9939370 doi: 10.1016/j.celrep.2023.111994
Medic, S. & Ziman, M. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). PLoS ONE 5(4), e9977 (2010).
pubmed: 20421967 pmcid: 2858648 doi: 10.1371/journal.pone.0009977
Nakazaki, H. et al. Key basic helix-loop-helix transcription factor genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. Dev. Biol. 316(2), 510–523 (2008).
pubmed: 18308300 doi: 10.1016/j.ydbio.2008.01.008
Luo, W. et al. Arterialization requires the timely suppression of cell growth. Nature 589(7842), 437–441 (2021).
pubmed: 33299176 doi: 10.1038/s41586-020-3018-x
Kofler, N. M., Cuervo, H., Uh, M. K., Murtomaki, A. & Kitajewski, J. Combined deficiency of Notch1 and Notch3 causes pericyte dysfunction, models CADASIL, and results in arteriovenous malformations. Sci. Rep. 5, 16449 (2015).
pubmed: 26563570 pmcid: 4643246 doi: 10.1038/srep16449
Hasan, S. S. et al. Endothelial Notch signalling limits angiogenesis via control of artery formation. Nat. Cell Biol. 19(8), 928–940 (2017).
pubmed: 28714969 pmcid: 5534340 doi: 10.1038/ncb3574
Conway, E. M., Collen, D. & Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49(3), 507–521 (2001).
pubmed: 11166264 doi: 10.1016/S0008-6363(00)00281-9
Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8(6), 464–478 (2007).
pubmed: 17522591 doi: 10.1038/nrm2183
Kofler, N. M. et al. Notch signaling in developmental and tumor angiogenesis. Genes Cancer 2(12), 1106–1116 (2011).
pubmed: 22866202 pmcid: 3411124 doi: 10.1177/1947601911423030
Tefft, J. B. et al. Notch1 and Notch3 coordinate for pericyte-induced stabilization of vasculature. Am. J. Physiol. Cell Physiol. 322(2), C185–C196 (2022).
pubmed: 34878922 doi: 10.1152/ajpcell.00320.2021
Domenga, V. et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 18(22), 2730–2735 (2004).
pubmed: 15545631 pmcid: 528893 doi: 10.1101/gad.308904
Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H. & Pech, M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell Biol. 125(4), 917–928 (1994).
pubmed: 7514607 doi: 10.1083/jcb.125.4.917
Kelly, B. J. et al. Churchill: An ultra-fast, deterministic, highly scalable and balanced parallelization strategy for the discovery of human genetic variation in clinical and population-scale genomics. Genome Biol. 16(1), 6 (2015).
pubmed: 25600152 pmcid: 4333267 doi: 10.1186/s13059-014-0577-x
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36(5), 411–420 (2018).
pubmed: 29608179 pmcid: 6700744 doi: 10.1038/nbt.4096
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177(7), 1888–1902 (2019).
pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031
Jin, S. et al. Inference and analysis of cell–cell communication using cell chat. Nat. Commun. 12(1), 1088 (2021).
pubmed: 33597522 doi: 10.1038/s41467-021-21246-9

Auteurs

Michelle A Wedemeyer (MA)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Department of Neurosurgery, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Neurosurgery, The Ohio State University College of Medicine, Columbus, OH, USA.

Tianli Ding (T)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Elizabeth A R Garfinkle (EAR)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Jesse J Westfall (JJ)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Jaye B Navarro (JB)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Maria Elena Hernandez Gonzalez (ME)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Elizabeth A Varga (EA)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Patricia Witman (P)

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Division of Dermatology, Nationwide Children's Hospital, Columbus, OH, USA.

Elaine R Mardis (ER)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Department of Neurosurgery, The Ohio State University College of Medicine, Columbus, OH, USA.

Catherine E Cottrell (CE)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA.

Anthony R Miller (AR)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

Katherine E Miller (KE)

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Katherine.Miller@nationwidechildrens.org.
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. Katherine.Miller@nationwidechildrens.org.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH